|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CMTM7 |
Gene summary for CMTM7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CMTM7 | Gene ID | 112616 |
| Gene name | CKLF like MARVEL transmembrane domain containing 7 | |
| Gene Alias | CKLFSF7 | |
| Cytomap | 3p22.3 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | A0A024R2L3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 112616 | CMTM7 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 1.47e-04 | 6.81e-01 | -0.0822 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:19031317 | Esophagus | ESCC | mononuclear cell differentiation | 226/8552 | 426/18723 | 1.20e-03 | 5.88e-03 | 226 |
| GO:00300984 | Esophagus | ESCC | lymphocyte differentiation | 192/8552 | 374/18723 | 1.52e-02 | 4.93e-02 | 192 |
| GO:19031311 | Lung | IAC | mononuclear cell differentiation | 66/2061 | 426/18723 | 2.63e-03 | 2.44e-02 | 66 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CMTM7 | SNV | Missense_Mutation | novel | c.471N>A | p.Ser157Arg | p.S157R | Q96FZ5 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CMTM7 | SNV | Missense_Mutation | c.499N>A | p.Val167Ile | p.V167I | Q96FZ5 | protein_coding | tolerated(0.82) | benign(0) | TCGA-BH-A209-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CMTM7 | insertion | In_Frame_Ins | novel | c.473_474insGGAATGGAATGGAATAGAATGGAAGCAAACTGAGTGCAGGGGAATGGA | p.Ile158delinsMetGluTrpAsnGlyIleGluTrpLysGlnThrGluCysArgGlyMetGlu | p.I158delinsMEWNGIEWKQTECRGME | Q96FZ5 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| CMTM7 | SNV | Missense_Mutation | c.331N>C | p.Ser111Pro | p.S111P | Q96FZ5 | protein_coding | deleterious(0.01) | possibly_damaging(0.653) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CMTM7 | SNV | Missense_Mutation | novel | c.407N>G | p.Asn136Ser | p.N136S | Q96FZ5 | protein_coding | tolerated(0.56) | benign(0.007) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CMTM7 | SNV | Missense_Mutation | novel | c.421N>A | p.Val141Ile | p.V141I | Q96FZ5 | protein_coding | tolerated(0.15) | benign(0.223) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| CMTM7 | SNV | Missense_Mutation | rs780296829 | c.250G>A | p.Asp84Asn | p.D84N | Q96FZ5 | protein_coding | tolerated(0.86) | benign(0.006) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| CMTM7 | SNV | Missense_Mutation | c.293G>A | p.Arg98His | p.R98H | Q96FZ5 | protein_coding | deleterious(0) | possibly_damaging(0.724) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CMTM7 | SNV | Missense_Mutation | rs767127146 | c.292N>T | p.Arg98Cys | p.R98C | Q96FZ5 | protein_coding | deleterious(0.01) | benign(0.061) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| CMTM7 | SNV | Missense_Mutation | rs377268191 | c.268N>A | p.Ala90Thr | p.A90T | Q96FZ5 | protein_coding | tolerated(0.06) | benign(0.01) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |